Breaking News
Sort by:
Top Post
Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine
Google Cloud has announced two new AI-powered life sciences solutions to accelerate drug discovery and […]
Chemotherapy May be Completed within 8 days with Two Doses of Polytaxel, an Innovative Anticancer Drug from South Korea's Biotech Firm
An innovative anticancer therapy that may complete chemotherapy with two doses of an anticancer drug […]
XtalPi and CK Life Sciences to collaborate in AI-empowered tumour vaccine research and development
XtalPi have announced that they are embarking on a strategic collaboration with CK Life Sciences, […]
Clarify Pharma Acquires Shares in Atai Life Sciences and Compass Pathways
Clarify Pharma, an investment vehicle specialising in biotech and life sciences companies seeking to prove […]
NHS To Roll Out Life-Extending Drug For Advanced Gastroesophageal Cancer
NHS comments on NICE decision to approve Nivolumab to treat rare forms of gastroesophageal cancer […]
Congruence Therapeutics Strengthens Leadership Team with Appointment of Dr. Sharath Hegde as Chief Scientific Officer
Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery […]
MilliporeSigma Invests $286 Million in U.S. Drug Safety Testing Capacity
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science […]
World’s First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks
A potential new drug to improve the long-term outcomes for patients who suffer heart attacks […]
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease
AbbVie announced the European Commission (EC) has approved SKYRIZI (risankizumab, 600 mg intravenous [IV] induction and […]
First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy
Telix Pharmaceuticals has announced that a first patient has been dosed in a Phase II […]
EmbarkNeuro Announces Initiation of Phase 2 Trial of ANC-501 for the Personalized Treatment of Depression (MDD)
EmbarkNeuro, a neuroscience-focused biotech company formerly known as Ancora Bio that was founded in 2021 […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more